174 related articles for article (PubMed ID: 24386264)
1. Prognostic significance of deregulated dicer expression in breast cancer.
Caffrey E; Ingoldsby H; Wall D; Webber M; Dinneen K; Murillo LS; Inderhaug C; Newell J; Gupta S; Callagy G
PLoS One; 2013; 8(12):e83724. PubMed ID: 24386264
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype.
Grelier G; Voirin N; Ay AS; Cox DG; Chabaud S; Treilleux I; Léon-Goddard S; Rimokh R; Mikaelian I; Venoux C; Puisieux A; Lasset C; Moyret-Lalle C
Br J Cancer; 2009 Aug; 101(4):673-83. PubMed ID: 19672267
[TBL] [Abstract][Full Text] [Related]
3. Loss of Dicer expression is associated with breast cancer progression and recurrence.
Khoshnaw SM; Rakha EA; Abdel-Fatah TM; Nolan CC; Hodi Z; Macmillan DR; Ellis IO; Green AR
Breast Cancer Res Treat; 2012 Sep; 135(2):403-13. PubMed ID: 22821364
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
5. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
6. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
[TBL] [Abstract][Full Text] [Related]
7. The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer.
Avery-Kiejda KA; Braye SG; Forbes JF; Scott RJ
BMC Cancer; 2014 Apr; 14():253. PubMed ID: 24725360
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
[TBL] [Abstract][Full Text] [Related]
9. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
15. Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison.
Spoelstra NS; Cittelly DM; Christenson JL; Gordon MA; Elias A; Jedlicka P; Richer JK
Hum Pathol; 2016 Oct; 56():40-51. PubMed ID: 27260947
[TBL] [Abstract][Full Text] [Related]
16. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Falck AK; Fernö M; Bendahl PO; Rydén L
World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
[TBL] [Abstract][Full Text] [Related]
17. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
18. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.
Dedes KJ; Natrajan R; Lambros MB; Geyer FC; Lopez-Garcia MA; Savage K; Jones RL; Reis-Filho JS
Eur J Cancer; 2011 Jan; 47(1):138-50. PubMed ID: 20832293
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
